Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriatic arthritis and plaque psoriasis. It works intracellularly to modulate inflammatory...
Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriatic arthritis and plaque psoriasis. It works intracellularly to modulate inflammatory mediator production without global immune suppression.
| Parameter | Specification |
|---|---|
| Chemical Name | Apremilast |
| CAS Number | 608141-41-9 |
| Molecular Formula | C₂₂H₂₄N₂O₇S |
| Molecular Weight | 460.50 g/mol |
| Purity | ≥ 99.5% |
| Appearance | White to off-white crystalline powder |
| Solubility | Practically insoluble in water |
| Grade | Pharmaceutical Grade |
| Storage | Store below 30°C |
| Batch Size | 10 grams to 250 kg lots |
| Available Documentation | CoA, CoO, DMF, MSDS |
Patent Notice: Products under patents are offered subject to the patent laws of the importing countries. The buyer is solely responsible for compliance with patent rights in any specific country.